GPCR Modulation in Breast Cancer

• Published in: International journal of molecular sciences Vol. 19; no. 12; p. 3840
• Main Authors: Lappano, Rosamaria, Jacquot, Yves, Maggiolini, Marcello
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 02.12.2018; MDPI
• Subjects: Amino acids; Biochemistry, Molecular Biology; Breast cancer; Cancer; Cancer therapies; Cell growth; Epidermal growth factor; Estrogens; Gene amplification; Kinases; Life Sciences; Ligands; Metastasis; Physiology; Proteins; Review; Tumorigenesis; Tumors; signal transduction; breast cancer; GPCRs
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms19123840

Breast cancer is the most prevalent cancer found in women living in developed countries. Endocrine therapy is the mainstay of treatment for hormone-responsive breast tumors (about 70% of all breast cancers) and implies the use of selective estrogen receptor modulators and aromatase inhibitors. In contrast, triple-negative breast cancer (TNBC), a highly heterogeneous disease that may account for up to 24% of all newly diagnosed cases, is hormone-independent and characterized by a poor prognosis. As drug resistance is common in all breast cancer subtypes despite the different treatment modalities, novel therapies targeting signaling transduction pathways involved in the processes of breast carcinogenesis, tumor promotion and metastasis have been subject to accurate consideration. G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors involved in the development and progression of many tumors including breast cancer. Here we discuss data regarding GPCR-mediated signaling, pharmacological properties and biological outputs toward breast cancer tumorigenesis and metastasis. Furthermore, we address several drugs that have shown an unexpected opportunity to interfere with GPCR-based breast tumorigenic signals.